Furthermore, patients deemed ineligible for traditional GemCis therapy or immunotherapy could be candidates for dose-decreased GemCis–anti-NPEPPS therapy as the addition of an NPEPPS inhibitor may lower the effective dose required to achieve similar intracellular platinum levels in cancer cells while offering some tumor specificity given that NPEPPS levels are higher in cancer cells compared to normal cells (12). This evidence concerns the gene NPEPPS and cancer.